drugset
drugset / Trial / NCT03544736

Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)

NCT03544736 ↗

Phase 1/2 Active not recruiting 30 enrolled Oslo University Hospital Bristol-Myers Squibb · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Three parallel cohort, multicenter, open-label, phase I/II clinical trial to analyze the safety and feasibility of PD-1 inhibition with Nivolumab given concomitantly with standard radiotherapy regimens in the treatment of esophageal cancer

Timeline

Start
2018-04-26
Primary completion
2025-12-31
Completion
2040-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody 240 mg Intravenous
Subject Nivolumab Monoclonal antibody 360 mg Intravenous
Subject Nivolumab Monoclonal antibody 480 mg Intravenous
Background Carboplatin Small molecule 2 unknown —
Background Paclitaxel Small molecule 50 mg/m2 Intravenous

Indications

esophageal cancer